心脉隆注射液联合达格列净对射血分数保留型心力衰竭合并2型糖尿病患者的心脏保护作用  

Cardioprotective Effect of Xinmailong Injection Combined with Dapagliflozin on Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus

作　　者：莫雁飞 杨姚瑶 黄磊 蒋斌[1] 刘静 王沣 王晓俊 王敏 MO Yanfei;YANG Yaoyao;HUANG Lei;JIANG Bin;LIU Jing;WANG Feng;WANG Xiaojun;WANG Min(Nanjing Pukou District Hospital of Traditional Chinese Medicine,Nanjing 210000,China;不详)

机构地区：[1]南京市浦口区中医院,江苏南京210000 [2]南京医科大学附属南京脑科医院

出　　处：《中外医学研究》2024年第5期127-132,共6页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：江苏卫生健康职业学院校级科研重点项目(JKC2021094);南京市浦口区社会事业科技发展项目(S2022-8)。

摘　　要：目的:探讨心脉隆注射液联合达格列净对射血分数保留型心力衰竭(HFpEF)合并2型糖尿病(T2DM)患者的心脏保护作用。方法:选择2021年10月1日—2022年12月31日于南京市浦口区中医院心内科、内分泌科和南京医科大学附属南京脑科医院老年医学科住院的120例HFpEF合并T2DM患者作为研究对象,根据治疗措施不同将患者分为常规治疗组(A组)、达格列净联合常规治疗组(B组)、心脉隆注射液联合常规治疗组(C组)与心脉隆注射液联合达格列净及常规治疗组(D组),排除随访资料不完整9例,最终纳入111例,A组28例,B组27例,C组26例,D组30例。比较四组治疗前及治疗后1个月、3个月左室射血分数(LVEF),二尖瓣舒张早期速度E波/二尖瓣瓣环舒张早期速度e'(E/e')、氨基末端蛋白脑钠肽前体(NT-proBNP)、6分钟步行试验距离(6MWD)及治疗效果、不良反应。结果:出院后1个月,D组LVEF、E/e'、6MWD改善优于A组,NT-proBNP水平优于A组和C组,差异有统计学意义(P<0.05);出院后3个月,B组、D组6MWD、LVEF、E/e'、NT-proBNP改善,且D组表现最优,差异有统计学意义(P<0.05)。四组总有效率比较,差异有统计学意义(P<0.05);D组总有效率高于A组和C组,差异有统计学意义(P<0.05)。四组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:HEpEF合并T2DM患者联合应用心脉隆注射液与达格列净治疗能发挥协同治疗作用,可更好地改善心功能、提高运动耐量,且安全性好。Objective:To investigate the cardioprotective effect of Xinmailong Injection combined with Dapagliflozin on patients with heart failure with preserved ejection fraction(HFpEF)and type 2 diabetes mellitus(T2DM).Method:A total of 120 patients with HFpEF and T2DM who hospitalized in the Department of Cardiology,Endocrinology of Nanjing Pukou District Hospital of Traditional Chinese Medicine and the Department of Geriatrics of the Affiliated Brain Hospital of Nanjing Medical Hospital from October 1,2021 to December 31,2022 were selected as subjects,the patients were divided into routine treatment group(group A),Dapagliflozin combined with routine treatment group(group B),Xinmailong Injection combined with routine treatment group(group C)and Xinmailong Injection combined with Dapagliflozin and routine treatment group(group D)according to the different treatment measures,excluding 9 cases with incomplete follow-up data,111 cases were finally included,28 cases in group A,27 cases in group B,26 cases in group C and 30 cases in group D.The left ventricular ejection fraction(LVEF),early diastolic velocity of mitral valve E wave/early diastolic velocity of mitral annulus e'(E/e'),amino terminal protein brain natriuretic peptide precursor(NT-proBNP),6 min walking test distance(6MWD)before treatment and 1 month and 3 months after treatment,therapeutic effect and adverse reactions were compared among four groups.Result:At 1 month after discharge,the improvement of LVEF,E/e'and 6 MWD in group D were better than those in group A,and the level of NT-proBNP was better than those in group A and group C,the differences were statistically significant(P<0.05);at 3 months after discharge,the 6MWD,LVEF,E/e'and NT-proBNP were improved in group B and group D,and the performance of group D was the best,the differences were statistically significant(P<0.05).There was a statistically significant difference in the total effective rate among the four groups(P<0.05);the total effective rate of group D was higher than those of group A and group

关 键 词：心脉隆注射液 达格列净 2型糖尿病 射血分数保留型心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病] R587.1[医药卫生—内科学]